NCT03314129Completed
Remediation of Visual Perceptual Impairments in People With Schizophrenia
Visual Remediation in Schizophrenia
Source: ClinicalTrials.gov · Last updated 5 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the effectiveness of a visual remediation intervention for people with schizophrenia. The intervention targets two visual functions that much research has shown are impaired in many people with the disorder, namely contrast sensitivity and perceptual organization. The first phase of the study will test the effects of interventions targeting each of these processes, as well as the effects of a combined package. A control condition of higher-level cognitive remediation is included as a fourth condition. The second phase of the study will evaluate the effectiveness of the most effective intervention from the first phase, but in a new and larger sample of individuals. Outcome measures include multiple aspects of visual functioning, as well as visual cognition and overall community functioning.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 79 (actual)
- First submitted
- 4 Oct 2017
- Start date
- 1 Jun 2018
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- University of Rochester
- Diseases
- Schizophrenia
- NCT number
- NCT03314129
What you commit to
- Study type: Interventional
- Participants enrolled: 79
- From 1 Jun 2018 to the primary completion date, 31 Mar 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- history of intellectual disability, or developmental or neurological disorder;
- history of brain trauma associated with loss of consciousness for \> 10 minutes or behavioral sequelae;
- alcohol or substance use disorder within the last 6 months; and
- history of eye disease (e.g., glaucoma, retinopathy).
Who the study is looking for
- SCID-5 diagnosis of schizophrenia;
- 18-60 years old;
- speaks English;
- able to complete the MATRICS Consensus Cognitive Battery (MCCB) at the baseline assessment (for R33);
- a raw score of 37 or greater on the Wide Range Achievement Test, Reading subtest (WRAT-3), to establish a minimum reading level (6th grade) and to estimate premorbid IQ; and
- clinically stable as indicated by no antipsychotic medication changes in the last month or if on depot, no change in the past 2 months.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester Medical Center - Strong Ties Community Support Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
| New York Presbyterian Hospital Coordinator of this site? Confirm its status | White Plains | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.